Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
Epizyme announced that researches have initiated treatment of a first patient in the Phase 2 clinical trial of its first-in-class EZH2 inhibitor, tazemetostat, in adults with malignant mesothelioma. ... Read more
Inhibitors of a specific receptor, P2X7, decrease tumor growth in malignant pleural mesothelioma, according to the results of a study titled “P2X7 targeting ... Read more